NCT03317223View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

January 21, 2019

Study Completion Date

January 24, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

CJ-12420/Clarithromycin/Amoxicillin

CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days

Trial Locations (1)

03722

Yonsei University Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT03317223 - A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients | Biotech Hunter | Biotech Hunter